The Effect of Probiotics on Infections in Toddlers

NCT ID: NCT00823056

Last Updated: 2012-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

454 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Probiotics has been known as a dietary supplement for a long period. Recent clinical trials indicate that probiotics might have an effect in preventing common infection diseases in children.

The investigators hypothesis is: if young children in the age of 6 month to 15 mdr. has a daily intake of a suspension containing probiotics in a period of 9 months, the incidence of diarrhoea and respiratory diseases can be reduced.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Probiotics has been known as a dietary supplement for a long period. Recent clinical trials indicate that probiotics might have an effect in preventing common infection diseases in children.

Our hypothesis is: if young healthy children in the age of 6 month to 15 mdr. has a daily intake of a suspension containing probiotics( BB12 and TH4) in a period of 9 months, the incidence of diarrhoea and respiratory diseases can be reduced.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diarrhoea Respiratory Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type PLACEBO_COMPARATOR

probiotics

Intervention Type DIETARY_SUPPLEMENT

placebo

2

Group Type ACTIVE_COMPARATOR

probiotics

Intervention Type DIETARY_SUPPLEMENT

0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

probiotics

placebo

Intervention Type DIETARY_SUPPLEMENT

probiotics

0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Children born in University Hospital Holbaek,Hospital North,Region Zealand, Denmark in the period of Jan. 2009 to Oct. 2010
* Gestational age \> 36. weeks

Exclusion Criteria

* Chronical heart or lung conditions
* Short Bowel Syndrome
* CVC (Central Venous Catheter)
Minimum Eligible Age

6 Months

Maximum Eligible Age

7 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Holbaek Sygehus

OTHER

Sponsor Role collaborator

Dept. of Microbiology, Slagelse University Hospital, Region Zealand,DK

UNKNOWN

Sponsor Role collaborator

Chr Hansen

INDUSTRY

Sponsor Role collaborator

Ferrosan A/S

UNKNOWN

Sponsor Role collaborator

Zealand University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Paediatr. Depart., Uni. Hosp. Holbaek, Region Zealand,DK, Uni. of CPH

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mette L. Gyhrs, MD.

Role: PRINCIPAL_INVESTIGATOR

ph.d student

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Paediatr. Depart., University Hospital Holbaek, University of Copenhagen

Holbæk, Region Sjælland, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Nielsen AC, Gyhrs ML, Nielsen LP, Pedersen C, Bottiger B. Gastroenteritis and the novel picornaviruses aichi virus, cosavirus, saffold virus, and salivirus in young children. J Clin Virol. 2013 Jul;57(3):239-42. doi: 10.1016/j.jcv.2013.03.015. Epub 2013 Apr 19.

Reference Type DERIVED
PMID: 23602437 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Version 2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prebiotic Effects in Healthy Toddlers
NCT05783141 RECRUITING NA